Brief: Eiger Announces Lonafarnib-Based Treatments In Phase 3 D-Livr Trial In Hepatitis Delta Virus Achieve Statistical Significance
08/12/2022 14:09
Dec 8 (Reuters) - Eiger BioPharmaceuticals Inc EIGR.O :
* EIGER ANNOUNCES BOTH LONAFARNIB-BASED TREATMENTS IN
PIVOTAL
PHASE 3 D-LIVR TRIAL IN HEPATITIS DELTA VIRUS (HDV) ACHIEVED
STATISTICAL SIGNIFICANCE AGAINST PLACEBO IN COMPOSITE PRIMARY
ENDPOINT
* EIGER BIOPHARMACEUTICALS INC - PLANS TO ENGAGE WITH
REGULATORY
AGENCIES, BEGINNING WITH A PRE-NDA MEETING WITH FDA ANTICIPATED
IN Q1 2023
* EIGER BIOPHARMACEUTICALS INC - INTENDS TO PRESENT D-LIVR
STUDY
RESULTS AT A FUTURE MEDICAL CONGRESS AND PUBLISH IN A
PEER-REVIEWED JOURNAL
Source text for Eikon: ID:nPnzzVT3a
Further company coverage: EIGR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eiger Biopharmaceuticals
See all newsBrief: Eiger Biopharmaceuticals On Sept 5, Bankruptcy Court Entered Order Confirming Fifth Amended Joint Plan Of Liquidation Of Co & Its Debtor Affiliates
Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar
Brief: Eiger Biopharmaceuticals And Amylyx Entered Into An Asset Purchase Agreement
Eiger BioPharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Eiger BioPharmaceuticals Inc expected to post a loss of $7.50 a share - Earnings Preview